Corimmun, a Germany-based drug development company backed by High-Tech Gründerfonds,, has been sold to Janssen-Cilag, part of the Janssen Pharmaceutical Companies of US-based pharmaceutical group Johnson & Johnson.

Corimmun received €680,000 ($855,000) of funding in 2008 from High-Tech Gründerfonds, Bayern Kapital and BioM in 2007.

Corimmun’s main product is Cor-1, a peptide for the treatment of heart failure.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?